Loading clinical trials...
Loading clinical trials...
A First-in-Human, Open-label, Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With Advanced-Stage, Relapsed/Refractory HER3-Expressing Solid Tumors
Conditions
Interventions
ENV-501
Locations
7
United States
Research Site
La Jolla, California, United States
Research Site
Indianapolis, Indiana, United States
Research Site
Farmington Hills, Michigan, United States
Research Site
Dallas, Texas, United States
Research Site
San Antonio, Texas, United States
Research Site
Campbelltown, New South Wales, Australia
Start Date
December 17, 2025
Primary Completion Date
July 1, 2027
Completion Date
July 1, 2027
Last Updated
March 2, 2026
NCT04541381
NCT05671510
NCT03137095
NCT07040891
NCT07547774
NCT06393374
Lead Sponsor
Hummingbird Bioscience
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions